10x Genomics
10x Genomics Inc is an American multinational life sciences technology enterprise specializing in the design, development, and commercialization of advanced instruments, consumables, and software for single-cell and spatial biology research. The company produces innovative genomic analysis platforms (such as Chromium and Visium) that enable researchers to interrogate biological systems at single-cell and subcellular resolution, driving breakthroughs in oncology, immunology, and neuroscience. Its core business operations encompass life sciences instrument engineering, microfluidic consumable manufacturing, bioinformatics software development, and global wholesale distribution. Revenue is derived primarily from instrument sales, consumable reagent kits, and recurring software licensing fees. 10x Genomics holds a dominant global market position in single-cell sequencing hardware and spatial biology solutions. The company is headquartered in Pleasanton, California, United States, and its Class A common stock trades on the Nasdaq Global Select Market under the ticker TXG.
7 of the funds FundTelligence covers report a position in 10x Genomics.
- Legal name
- 10x Genomics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Genomics & Profiling, Precision Medicine & Genomics, Single-Cell & Multiomics
Funds holding 10x Genomics
- Pensum Kairos — Pensum · 2.28 % (full portfolio disclosed, June 2026)
- T. Rowe Price Global Focused Growth Equity Fund — T. Rowe Price · 1.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.68 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.46 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.12 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.09 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)